DNLI: AVLAYAH's launch validates a brain-targeted biologics platform, driving pipeline and global expansion
Competition in blood-brain barrier therapies is intensifying, driving innovation and benefiting patients. AVLAYAH's launch validates the TransportVehicle platform, enabling expansion into new indications and global markets. AI and U.S.-based manufacturing enhance efficiency and adaptability.Based o…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.